All In Biotech

NDA 022500 · Rosemont

Nexiclon Xr

Clonidine · Oral · Central alpha-2 Adrenergic Agonist

Last checked: Nov 19, 2026Latest source record: Sep 23, 2010 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Dec 3, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

276

54 Phase 3, 19 recruiting

FAERS reports

51,063

35,861 serious, 6,117 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 15, 2026.

NEXICLON XR is indicated in the treatment of hypertension. NEXICLON XR may be employed alone or concomitantly with other antihypertensive agents. NEXICLON XR is a central alpha-adrenergic agonist indicated for: Treatment of hypertension ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • NEXICLON XR · CLONIDINE EQ 0.17MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • NEXICLON XR · CLONIDINE EQ 0.26MG BASE · TABLET, EXTENDED RELEASE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Clonidine" as an intervention, any sponsor and status, largest first.

All 276 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,905
  • pain3,144
  • nausea3,068
  • fatigue3,049
  • off label use3,046
  • headache2,949
  • hypertension2,704
  • dyspnoea2,376
  • diarrhoea2,359
  • vomiting2,146
  • chronic kidney disease2,116
  • dizziness1,934

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004509
2005983
2006964
2007945
2008929
20091,298
20101,558
20111,792
20121,951
20131,768
20142,447
20152,894
20163,175
20173,151
20183,590
20193,735
20203,082
20212,798
20222,534
20232,813
20242,943
20252,899
20262,305

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,240 on PubMed

Sponsor: Rosemont

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.